ArticleFrontiers in microbiology2020
Ultra-Short Antimicrobial Peptoids Show Propensity for Membrane Activity Against Multi-Drug Resistant
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Optimized LL-37-Derived Peptides Exhibit Antitubercular Activity, Induce Membrane Disruption, and P-Type ATPase Transcriptional Responses inBiomolecules · 2026Article
- The rise of ultrashort cationic β-peptides as promising antimicrobial therapeutics.RSC medicinal chemistry · 2025Review
- Structural Optimization of Antifungal Peptoids targetingACS medicinal chemistry letters · 2025Article
- Uprising Unconventional Nanobiomaterials: Peptoid Nanosheets as a Multi-Modular Platform for Advanced Biological Studies.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Structural and functional analysis of Escherichia coli membrane disruption by Ib-M peptides.PloS one · 2025Article
- Failure or future? Exploring alternative antibacterials: a comparative analysis of antibiotics and naturally derived biopolymers.Frontiers in microbiology · 2025Review
- Article
- Review: Structure-Activity Relationship of Antimicrobial Peptoids.Pharmaceutics · 2023Review
- Review
- Article
- Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?Frontiers in immunology · 2022Review
- Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery.Microorganisms · 2021Review
- Structural Diversity of Peptoids: Tube-Like Structures of Macrocycles.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Tuberculosis (TB) results in both morbidity and mortality on a global scale. With drug resistance on the increase, there is an urgent need to develop novel anti-mycobacterials. Thus, we assessed the anti-mycobacterial potency of three novel synthetic peptoids against drug-susceptible and multi-drug resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.